Ally Bridge Group NY LLC Takes $1.55 Million Position in Whitehawk Therapeutics, Inc. $WHWK

Ally Bridge Group NY LLC acquired a new stake in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 817,939 shares of the company’s stock, valued at approximately $1,554,000. Whitehawk Therapeutics accounts for 0.9% of Ally Bridge Group NY LLC’s investment portfolio, making the stock its 20th largest holding. Ally Bridge Group NY LLC owned approximately 1.74% of Whitehawk Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. ABG Innovation Capital Partners III GP Ltd purchased a new stake in Whitehawk Therapeutics during the third quarter worth about $51,000. Dimensional Fund Advisors LP purchased a new position in Whitehawk Therapeutics in the third quarter valued at about $84,000. Squarepoint Ops LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at approximately $159,000. Bridgeway Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at approximately $409,000. Finally, Peapod Lane Capital LLC purchased a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth approximately $577,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Trading Up 0.3%

NASDAQ:WHWK opened at $3.91 on Friday. The company has a market capitalization of $184.28 million, a P/E ratio of 8.32 and a beta of 0.51. The firm has a 50-day moving average price of $3.02 and a two-hundred day moving average price of $2.48. Whitehawk Therapeutics, Inc. has a twelve month low of $1.39 and a twelve month high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.21.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Monday, December 29th. JonesTrading began coverage on Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price on the stock. Finally, Oppenheimer began coverage on Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $6.50.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.